We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




New Testing Strips to Make Rapid Antigen Testing as Powerful as PCR Testing

By LabMedica International staff writers
Posted on 06 Mar 2024

During the onset of the pandemic, individuals experiencing symptoms had to endure lengthy queues for lab-based PCR testing and then wait around two days for the results, to confirm if they were infected with the COVID-19 virus. More...

This process was not only inconvenient but also involved complex and costly logistics, contributing to testing delays and increasing the risk of spreading the disease. Now, a newly developed biosensing technology enables the creation of gene test strips that can match the quality of traditional lab-based tests.

The new technology developed by a team of biomedical engineers at UNSW Sydney (Sydney, Australia) offers test strips that are as accurate as lab-based PCR tests, with the added advantage of quick, on-site disease detection. Described by the researchers as having “PCR in your pocket,” this advancement holds potential for broad applications in biomedical and environmental diagnostics across various sectors, including food, agriculture, and biosafety management. The technology allows for the detection of specific gene sequences at room temperature, using test strips that resemble the familiar RAT Covid test, potentially eliminating the need for long queues at PCR testing centers and drastically reducing costs to a few dollars per test. The test strips could be instrumental in rapidly responding to new pathogens, identifying areas with high antibiotic resistance, or in conservation efforts for endangered species.

The process of achieving PCR-level accuracy with these new test strips involves the creation of minuscule DNA nano-circles, each containing a fragment of the target DNA, such as the COVID virus. These nano-circles, approximately 2 nanometres in size, are then combined with CRISPR/Cas proteins, which are programmed to interact specifically with the target pathogen's DNA. When these proteins encounter the target DNA, they cause the DNA nano-circles to linearize, creating an abundance of 'fake targets.' This method triggers a molecular chain reaction, resulting in a flood of these fake targets that are easily detectable by the test strips, even with minimal presence of the original gene target.

This technology has been demonstrated to accurately detect COVID-19 virus and Helicobacter bacteria, which are responsible for stomach ulcers. Potential applications of this biosensing method extend beyond health diagnostics to include biosecurity (detecting invasive marine species), environmental science (tracking threatened species through DNA testing of environmental samples), and even cancer diagnosis, as demonstrated by the team's successful detection of cancer mutations in clinical patient samples.

“We think we created a new benchmark in biosensing – our gene-based tests will be able to be performed anywhere, anytime, by virtually anyone,” said study author Dr. Fei Deng.

Related Links:
UNSW Sydney


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Acute lymphoblastic leukemia in children and young people requires careful relapse risk assessment as treatment expands beyond standard chemotherapy. (Image Credit: Shutterstock)

New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL

Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Decentralized Laboratory Network Improves Detection of Viral Hemorrhagic Fevers in Guinea

Viral hemorrhagic fevers remain a major diagnostic challenge in West Africa because their early symptoms can resemble those of other febrile illnesses. The 2014–2016 Ebola epidemic underscored the need... Read more

Pathology

view channel
Image Credit: Adobe Stock

AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification

In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.